# SEER CANCER COMPLETE SITE-HISTOLOGY CATALOG
## All ICD-O-3 Cancer Types - Site and Morphology Codes

**Purpose:** Complete reference catalog of all cancer site-histology combinations tracked by SEER using ICD-O-3 coding

**Last Updated:** November 13, 2025
**ICD-O Version:** ICD-O-3.2 (2021+) / Cancer PathCHART 2024 (2024+)
**SEER Registries:** 22 registries covering ~48% of US population
**Total Cancer Types:** 1,000+ unique site-histology combinations
**Topography Codes:** C00.0 - C80.9 (primary anatomic sites)
**Morphology Codes:** 8000/0 - 9989/3 (histology + behavior)

---

## üì• ACCESS COMPLETE OFFICIAL CODE LISTS

### **Primary Sources:**

1. **SEER ICD-O-3 Coding Materials:**
   - Main page: https://seer.cancer.gov/icd-o-3/
   - **2024 Cancer PathCHART Site-Morphology Validation List:** Official standard for 2024+ cases
   - **ICD-O-3 SEER Site/Histology Validation List (2022):** For 2021-2023 cases
   - **Download:** PDF (680 KB) and Excel (442 KB) formats

2. **WHO ICD-O-3.2 Official Manual:**
   - WHO page: https://www.who.int/standards/classifications/other-classifications/international-classification-of-diseases-for-oncology
   - IARC electronic version: https://www.iarc.fr/

3. **SEER Site Recode:**
   - ICD-O-3/WHO 2008: https://seer.cancer.gov/siterecode/icdo3_dwhoheme/
   - Groupings for analysis: https://seer.cancer.gov/siterecode/

4. **NAACCR ICD-O-3 Guidelines:**
   - Standards: https://www.naaccr.org/icdo3/
   - Updates: https://www.naaccr.org/

5. **SEER*Stat Variable Dictionary:**
   - Complete variable definitions: https://seer.cancer.gov/data-software/documentation/seerstat/

---

## üóÇÔ∏è ICD-O-3 CODING SYSTEM STRUCTURE

### **Multi-Axial Classification:**

ICD-O-3 uses a **4-axis system** for tumor classification:

1. **Topography (T):** Anatomic site where tumor originated (C codes)
2. **Morphology (M):** Histologic type of tumor (4-digit codes)
3. **Behavior (B):** Malignancy/invasiveness (5th digit: /0, /1, /2, /3, /6, /9)
4. **Grade/Differentiation (G):** Tumor differentiation (optional 6th digit)

### **Complete Tumor Code Format:**
```
C50.4    8500/3    G2
  ‚Üì        ‚Üì       ‚Üì
 Site  Histology  Grade
       + Behavior
```

**Example:** C50.4 8500/3 = Invasive ductal carcinoma of upper-outer quadrant of breast

---

## üìç TOPOGRAPHY CODES (PRIMARY SITE: C00.0 - C80.9)

**Structure:** C [site code].[subsite code]
**Total codes:** 400+ specific anatomic subsites

### **Major Anatomic Site Categories:**

| ICD-O-3 Code Range | Body System/Region | Number of Subsites |
|--------------------|--------------------|--------------------|
| **C00-C14** | Lip, Oral Cavity, Pharynx | 60+ subsites |
| **C15-C26** | Digestive Organs | 80+ subsites |
| **C30-C39** | Respiratory & Intrathoracic | 40+ subsites |
| **C40-C41** | Bone & Articular Cartilage | 30+ subsites |
| **C42-C49** | Soft Tissue, Peripheral Nerves | 40+ subsites |
| **C50** | Breast | 10 subsites |
| **C51-C58** | Female Genital Organs | 40+ subsites |
| **C60-C63** | Male Genital Organs | 30+ subsites |
| **C64-C68** | Urinary Tract | 30+ subsites |
| **C69** | Eye & Adnexa | 20+ subsites |
| **C70-C72** | Brain & Central Nervous System | 30+ subsites |
| **C73-C75** | Endocrine Glands | 20+ subsites |
| **C76-C80** | Ill-defined & Unknown Sites | 20+ subsites |

### **Detailed Site Examples:**

#### **1. HEAD AND NECK (C00-C14):**

| Code | Site | Common Cancers |
|------|------|----------------|
| C00.0-C00.9 | Lip | Squamous cell carcinoma |
| C01 | Base of tongue | Squamous cell carcinoma |
| C02.0-C02.9 | Tongue (other parts) | Squamous cell carcinoma |
| C03.0-C03.9 | Gum | Squamous cell carcinoma |
| C04.0-C04.9 | Floor of mouth | Squamous cell carcinoma |
| C05.0-C05.9 | Palate | Squamous cell carcinoma |
| C06.0-C06.9 | Mouth (other) | Squamous cell carcinoma |
| C07 | Parotid gland | Mucoepidermoid carcinoma, adenoid cystic |
| C08.0-C08.9 | Salivary glands (other) | Adenocarcinoma |
| C09.0-C09.9 | Tonsil | Squamous cell carcinoma |
| C10.0-C10.9 | Oropharynx | Squamous cell carcinoma (HPV-associated) |
| C11.0-C11.9 | Nasopharynx | Nasopharyngeal carcinoma |
| C12 | Pyriform sinus | Squamous cell carcinoma |
| C13.0-C13.9 | Hypopharynx | Squamous cell carcinoma |
| C14.0-C14.2 | Pharynx (other) | Squamous cell carcinoma |

#### **2. DIGESTIVE SYSTEM (C15-C26):**

| Code | Site | Common Cancers |
|------|------|----------------|
| C15.0-C15.9 | Esophagus | Adenocarcinoma, squamous cell carcinoma |
| C16.0-C16.9 | Stomach | Adenocarcinoma, GIST, lymphoma |
| C17.0-C17.9 | Small intestine | Adenocarcinoma, carcinoid, GIST |
| C18.0-C18.9 | Colon | Adenocarcinoma |
| C19 | Rectosigmoid junction | Adenocarcinoma |
| C20 | Rectum | Adenocarcinoma |
| C21.0-C21.8 | Anus & anal canal | Squamous cell carcinoma (HPV-associated) |
| C22.0-C22.1 | Liver | Hepatocellular carcinoma, cholangiocarcinoma |
| C23 | Gallbladder | Adenocarcinoma |
| C24.0-C24.9 | Biliary tract | Cholangiocarcinoma |
| C25.0-C25.9 | Pancreas | Adenocarcinoma (ductal), neuroendocrine |
| C26.0-C26.9 | GI tract (other/NOS) | Various |

#### **3. RESPIRATORY SYSTEM (C30-C39):**

| Code | Site | Common Cancers |
|------|------|----------------|
| C30.0-C30.1 | Nasal cavity & sinuses | Squamous cell, adenocarcinoma |
| C31.0-C31.9 | Paranasal sinuses | Squamous cell carcinoma |
| C32.0-C32.9 | Larynx | Squamous cell carcinoma |
| C33 | Trachea | Squamous cell, adenoid cystic |
| C34.0-C34.9 | Lung & bronchus | Adenocarcinoma, squamous cell, small cell, large cell |
| C37 | Thymus | Thymoma, thymic carcinoma |
| C38.0-C38.8 | Heart, mediastinum, pleura | Mesothelioma, sarcoma |

#### **4. BONE & SOFT TISSUE (C40-C49):**

| Code | Site | Common Cancers |
|------|------|----------------|
| C40.0-C40.9 | Bones of limbs | Osteosarcoma, Ewing sarcoma, chondrosarcoma |
| C41.0-C41.9 | Bones (other: skull, vertebra, pelvis) | Osteosarcoma, chordoma, chondrosarcoma |
| C47.0-C47.9 | Peripheral nerves | Malignant peripheral nerve sheath tumor (MPNST) |
| C48.0-C48.2 | Retroperitoneum & peritoneum | Sarcoma, mesothelioma |
| C49.0-C49.9 | Connective & soft tissue | Liposarcoma, leiomyosarcoma, fibrosarcoma, GIST |

#### **5. BREAST (C50):**

| Code | Site | Common Cancers |
|------|------|----------------|
| C50.0 | Nipple | Paget disease, ductal carcinoma |
| C50.1 | Central portion | Ductal carcinoma in situ (DCIS), invasive ductal |
| C50.2 | Upper-inner quadrant | Invasive ductal, invasive lobular |
| C50.3 | Lower-inner quadrant | Invasive ductal, invasive lobular |
| C50.4 | Upper-outer quadrant | Invasive ductal (most common location) |
| C50.5 | Lower-outer quadrant | Invasive ductal, invasive lobular |
| C50.6 | Axillary tail | Invasive ductal, invasive lobular |
| C50.8 | Overlapping lesion | Invasive ductal, invasive lobular |
| C50.9 | Breast, NOS | Various |

#### **6. FEMALE GENITAL (C51-C58):**

| Code | Site | Common Cancers |
|------|------|----------------|
| C51.0-C51.9 | Vulva | Squamous cell carcinoma |
| C52 | Vagina | Squamous cell carcinoma, clear cell (DES-related) |
| C53.0-C53.9 | Cervix uteri | Squamous cell carcinoma, adenocarcinoma (HPV-associated) |
| C54.0-C54.9 | Corpus uteri | Endometrial adenocarcinoma, carcinosarcoma |
| C55 | Uterus, NOS | Endometrial carcinoma, sarcoma |
| C56 | Ovary | Serous, mucinous, endometrioid, clear cell carcinoma |
| C57.0-C57.9 | Fallopian tube, broad ligament | Serous carcinoma |
| C58 | Placenta | Choriocarcinoma, gestational trophoblastic disease |

#### **7. MALE GENITAL (C60-C63):**

| Code | Site | Common Cancers |
|------|------|----------------|
| C60.0-C60.9 | Penis | Squamous cell carcinoma |
| C61 | Prostate gland | Adenocarcinoma |
| C62.0-C62.9 | Testis | Seminoma, nonseminomatous germ cell tumors |
| C63.0-C63.9 | Epididymis, spermatic cord | Sarcoma, adenocarcinoma |

#### **8. URINARY SYSTEM (C64-C68):**

| Code | Site | Common Cancers |
|------|------|----------------|
| C64 | Kidney | Renal cell carcinoma (clear cell, papillary, chromophobe) |
| C65 | Renal pelvis | Urothelial carcinoma |
| C66 | Ureter | Urothelial carcinoma |
| C67.0-C67.9 | Bladder | Urothelial carcinoma |
| C68.0-C68.9 | Urinary organs (other) | Urothelial carcinoma |

#### **9. EYE & BRAIN (C69-C72):**

| Code | Site | Common Cancers |
|------|------|----------------|
| C69.0-C69.9 | Eye & adnexa | Melanoma, retinoblastoma |
| C70.0-C70.9 | Meninges | Meningioma, meningeal sarcoma |
| C71.0-C71.9 | Brain | Glioblastoma, astrocytoma, ependymoma, medulloblastoma |
| C72.0-C72.9 | Spinal cord & CNS | Astrocytoma, ependymoma |

#### **10. ENDOCRINE (C73-C75):**

| Code | Site | Common Cancers |
|------|------|----------------|
| C73 | Thyroid gland | Papillary, follicular, medullary, anaplastic carcinoma |
| C74.0-C74.9 | Adrenal gland | Adrenocortical carcinoma, pheochromocytoma |
| C75.0-C75.9 | Pituitary, pineal, parathyroid | Adenoma, carcinoma |

---

## üî¨ MORPHOLOGY CODES (HISTOLOGY: 8000/0 - 9989/3)

**Structure:** [4-digit histology]/[1-digit behavior]
**Total codes:** 500+ histologic types √ó 6 behavior codes = 3,000+ combinations

### **Behavior Codes (5th digit):**

| Code | Behavior | Definition |
|------|----------|------------|
| **/0** | Benign | Non-invasive, non-malignant |
| **/1** | Uncertain/Borderline | Uncertain malignant potential |
| **/2** | Carcinoma in situ (CIS) | Non-invasive but malignant cells |
| **/3** | Malignant, primary site | Invasive malignant tumor |
| **/6** | Malignant, metastatic | Secondary/metastatic tumor |
| **/9** | Malignant, uncertain primary/metastatic | Uncertain if primary or met |

### **Major Histologic Type Categories:**

#### **1. EPITHELIAL NEOPLASMS (8000-8799):**

**Carcinomas, NOS (8000-8009):**
- 8000/3: Neoplasm, malignant
- 8001/3: Tumor cells, malignant
- 8010/2: Carcinoma in situ, NOS
- 8010/3: Carcinoma, NOS

**Squamous Cell Carcinomas (8050-8089):**
- 8050/3: Papillary squamous cell carcinoma
- 8051/3: Verrucous carcinoma, NOS
- 8052/3: Papillary squamous cell carcinoma, non-invasive
- 8070/2: Squamous cell carcinoma in situ, NOS
- 8070/3: Squamous cell carcinoma, NOS
- 8071/3: Squamous cell carcinoma, keratinizing, NOS
- 8072/3: Squamous cell carcinoma, large cell, nonkeratinizing, NOS
- 8073/3: Squamous cell carcinoma, small cell, nonkeratinizing
- 8074/3: Squamous cell carcinoma, spindle cell
- 8075/3: Squamous cell carcinoma, adenoid
- 8076/3: Squamous cell carcinoma, microinvasive
- 8077/2: Squamous intraepithelial neoplasia, grade III
- 8078/3: Squamous cell carcinoma with horn formation

**Basal Cell Carcinomas (8090-8110):**
- 8090/3: Basal cell carcinoma, NOS
- 8091/3: Multifocal superficial basal cell carcinoma
- 8092/3: Infiltrating basal cell carcinoma, NOS
- 8093/3: Basal cell carcinoma, fibroepithelial
- 8094/3: Basosquamous carcinoma
- 8095/3: Metatypical carcinoma
- 8097/3: Basal cell carcinoma, nodular
- 8098/3: Adenoid basal carcinoma

**Transitional Cell (Urothelial) Carcinomas (8120-8139):**
- 8120/2: Transitional cell carcinoma in situ
- 8120/3: Transitional cell carcinoma, NOS (urothelial)
- 8121/3: Transitional cell carcinoma, Schneiderian type
- 8122/3: Transitional cell carcinoma, spindle cell
- 8123/3: Basaloid carcinoma
- 8124/3: Cloacogenic carcinoma
- 8130/2: Papillary transitional cell carcinoma, non-invasive
- 8130/3: Papillary transitional cell carcinoma
- 8131/3: Transitional cell carcinoma, micropapillary

**Adenocarcinomas (8140-8389):**
- 8140/2: Adenocarcinoma in situ, NOS
- 8140/3: Adenocarcinoma, NOS
- 8141/3: Scirrhous adenocarcinoma
- 8144/3: Adenocarcinoma, intestinal type
- 8145/3: Carcinoma, diffuse type
- 8147/3: Basal cell adenocarcinoma
- 8200/3: Adenoid cystic carcinoma
- 8201/3: Cribriform carcinoma, NOS
- 8211/3: Tubular adenocarcinoma
- 8230/3: Solid carcinoma, NOS
- 8240/3: Carcinoid tumor, NOS
- 8246/3: Neuroendocrine carcinoma, NOS
- 8247/3: Merkel cell carcinoma
- 8249/3: Atypical carcinoid tumor
- 8260/3: Papillary adenocarcinoma, NOS
- 8290/3: Oxyphilic adenocarcinoma
- 8310/3: Clear cell adenocarcinoma, NOS
- 8323/3: Mixed cell adenocarcinoma
- 8333/3: Fetal adenocarcinoma
- 8380/3: Endometrioid adenocarcinoma, NOS
- 8390/3: Skin appendage carcinoma

**Mucoepidermoid & Cystic Carcinomas (8430-8440):**
- 8430/3: Mucoepidermoid carcinoma
- 8440/3: Cystadenocarcinoma, NOS

**Papillary & Serous Carcinomas (8450-8460):**
- 8450/3: Papillary cystadenocarcinoma, NOS
- 8460/3: Serous surface papillary carcinoma
- 8461/3: Serous adenocarcinoma, NOS
- 8462/3: Papillary serous cystadenocarcinoma

**Mucinous Adenocarcinomas (8470-8490):**
- 8470/2: Mucinous cystadenocarcinoma, non-invasive
- 8470/3: Mucinous cystadenocarcinoma, NOS
- 8480/3: Mucinous adenocarcinoma
- 8481/3: Mucin-producing adenocarcinoma
- 8490/3: Signet ring cell carcinoma

**Ductal & Lobular Carcinomas (8500-8520):**
- 8500/2: Intraductal carcinoma, noninfiltrating, NOS
- 8500/3: Invasive ductal carcinoma, NOS
- 8501/2: Comedocarcinoma, noninfiltrating
- 8501/3: Comedocarcinoma, NOS
- 8502/3: Secretory carcinoma of breast
- 8503/2: Intraductal papillary adenocarcinoma, noninfiltrating
- 8503/3: Intraductal papillary adenocarcinoma with invasion
- 8504/2: Intracystic papillary adenocarcinoma, noninfiltrating
- 8507/2: Micropapillary carcinoma, noninvasive
- 8520/2: Lobular carcinoma in situ, NOS
- 8520/3: Lobular carcinoma, NOS
- 8521/3: Infiltrating ductular carcinoma

#### **2. SOFT TISSUE SARCOMAS (8800-8936):**

**Sarcomas, NOS (8800-8810):**
- 8800/3: Sarcoma, NOS
- 8801/3: Spindle cell sarcoma
- 8802/3: Giant cell sarcoma
- 8803/3: Small cell sarcoma
- 8804/3: Epithelioid sarcoma
- 8805/3: Undifferentiated sarcoma
- 8806/3: Desmoplastic small round cell tumor

**Fibrosarcomas (8810-8815):**
- 8810/3: Fibrosarcoma, NOS
- 8814/3: Infantile fibrosarcoma
- 8815/3: Solitary fibrous tumor, malignant

**Liposarcomas (8850-8861):**
- 8850/3: Liposarcoma, NOS
- 8851/3: Liposarcoma, well differentiated
- 8852/3: Myxoid liposarcoma
- 8853/3: Round cell liposarcoma
- 8854/3: Pleomorphic liposarcoma
- 8855/3: Mixed type liposarcoma
- 8858/3: Dedifferentiated liposarcoma

**Leiomyosarcomas (8890-8896):**
- 8890/3: Leiomyosarcoma, NOS
- 8891/3: Epithelioid leiomyosarcoma
- 8894/3: Angiomyosarcoma
- 8895/3: Myosarcoma
- 8896/3: Myxoid leiomyosarcoma

**Rhabdomyosarcomas (8900-8921):**
- 8900/3: Rhabdomyosarcoma, NOS
- 8901/3: Pleomorphic rhabdomyosarcoma
- 8902/3: Mixed type rhabdomyosarcoma
- 8910/3: Embryonal rhabdomyosarcoma, NOS
- 8912/3: Spindle cell rhabdomyosarcoma
- 8920/3: Alveolar rhabdomyosarcoma

#### **3. GERM CELL & TROPHOBLASTIC TUMORS (9060-9105):**

- 9060/3: Dysgerminoma
- 9061/3: Seminoma, NOS
- 9062/3: Seminoma, anaplastic
- 9064/3: Germinoma
- 9065/3: Germ cell tumor, nonseminomatous
- 9070/3: Embryonal carcinoma, NOS
- 9071/3: Yolk sac tumor
- 9072/3: Polyembryoma
- 9080/0: Teratoma, benign
- 9080/3: Teratoma, malignant, NOS
- 9082/3: Malignant teratoma, undifferentiated
- 9084/3: Teratoma with malignant transformation
- 9085/3: Mixed germ cell tumor
- 9100/3: Choriocarcinoma, NOS
- 9101/3: Choriocarcinoma combined with other germ cell elements

#### **4. LYMPHOMAS (9590-9699, 9700-9729):**

**Hodgkin Lymphomas (9650-9667):**
- 9650/3: Hodgkin lymphoma, NOS
- 9651/3: Hodgkin lymphoma, lymphocyte-rich
- 9652/3: Hodgkin lymphoma, mixed cellularity, NOS
- 9653/3: Hodgkin lymphoma, lymphocyte depletion, NOS
- 9663/3: Hodgkin lymphoma, nodular sclerosis, NOS
- 9665/3: Hodgkin lymphoma, nodular sclerosis, grade 1
- 9667/3: Hodgkin lymphoma, nodular sclerosis, grade 2

**Non-Hodgkin Lymphomas - B-cell (9670-9699):**
- 9670/3: Small lymphocytic lymphoma
- 9671/3: Malignant lymphoma, lymphoplasmacytic
- 9673/3: Mantle cell lymphoma
- 9675/3: Malignant lymphoma, mixed small and large cell, diffuse
- 9678/3: Primary effusion lymphoma
- 9679/3: Mediastinal large B-cell lymphoma
- 9680/3: Diffuse large B-cell lymphoma, NOS
- 9684/3: Immunoblastic lymphoma, NOS
- 9687/3: Burkitt lymphoma, NOS
- 9689/3: Splenic marginal zone lymphoma
- 9690/3: Follicular lymphoma, NOS
- 9695/3: Follicular lymphoma, grade 1
- 9698/3: Follicular lymphoma, grade 3
- 9699/3: Marginal zone B-cell lymphoma, NOS

**Non-Hodgkin Lymphomas - T-cell & NK-cell (9700-9729):**
- 9700/3: Mycosis fungoides
- 9701/3: S√©zary syndrome
- 9702/3: Mature T-cell lymphoma, NOS
- 9705/3: Angioimmunoblastic T-cell lymphoma
- 9708/3: Subcutaneous panniculitis-like T-cell lymphoma
- 9709/3: Cutaneous T-cell lymphoma, NOS
- 9714/3: Anaplastic large cell lymphoma, T-cell and Null-cell types
- 9716/3: Hepatosplenic gamma-delta cell lymphoma
- 9717/3: Intestinal T-cell lymphoma, NOS
- 9718/3: Primary cutaneous CD30-positive T-cell proliferations
- 9719/3: NK/T-cell lymphoma, nasal and nasal-type

#### **5. LEUKEMIAS (9733-9948):**

**Lymphoid Leukemias (9733-9831):**
- 9733/3: Precursor T-cell lymphoblastic leukemia
- 9811/3: B lymphoblastic leukemia/lymphoma, NOS
- 9823/3: B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma
- 9826/3: Burkitt cell leukemia
- 9831/3: T-cell large granular lymphocytic leukemia
- 9832/3: Prolymphocytic leukemia, NOS

**Myeloid Leukemias (9860-9931):**
- 9860/3: Myeloid leukemia, NOS
- 9861/3: Acute myeloid leukemia, NOS
- 9865/3: Acute myeloid leukemia with t(6;9)(p23;q34); DEK-NUC214
- 9866/3: Acute promyelocytic leukemia, t(15;17)(q22;q12)
- 9867/3: Acute myelomonocytic leukemia
- 9870/3: Acute basophilic leukemia
- 9871/3: Acute myeloid leukemia with abnormal marrow eosinophils
- 9872/3: Acute myeloid leukemia, minimal differentiation
- 9873/3: Acute myeloid leukemia without maturation
- 9874/3: Acute myeloid leukemia with maturation
- 9891/3: Acute monocytic leukemia
- 9895/3: Acute myeloid leukemia with multilineage dysplasia
- 9896/3: Acute myeloid leukemia, t(8;21)(q22;q22)
- 9897/3: Acute myeloid leukemia, 11q23 abnormalities
- 9910/3: Acute megakaryoblastic leukemia
- 9920/3: Therapy-related myeloid neoplasm
- 9930/3: Myeloid sarcoma
- 9931/3: Acute panmyelosis with myelofibrosis

**Chronic Myeloproliferative (9945-9946):**
- 9945/3: Chronic myelomonocytic leukemia, NOS
- 9946/3: Juvenile myelomonocytic leukemia

#### **6. MELANOMAS (8720-8790):**

- 8720/2: Malignant melanoma in situ
- 8720/3: Malignant melanoma, NOS
- 8721/3: Nodular melanoma
- 8722/3: Balloon cell melanoma
- 8723/3: Malignant melanoma, regressing
- 8730/3: Amelanotic melanoma
- 8740/3: Malignant melanoma in junctional nevus
- 8741/2: Precancerous melanosis, NOS
- 8741/3: Malignant melanoma in precancerous melanosis
- 8742/2: Lentigo maligna
- 8742/3: Lentigo maligna melanoma
- 8743/3: Superficial spreading melanoma
- 8744/3: Acral lentiginous melanoma, malignant
- 8745/3: Desmoplastic melanoma, malignant
- 8746/3: Mucosal lentiginous melanoma
- 8761/3: Giant congenital nevus, malignant
- 8770/3: Mixed epithelioid and spindle cell melanoma
- 8771/3: Epithelioid cell melanoma
- 8772/3: Spindle cell melanoma, NOS
- 8773/3: Spindle cell melanoma, type A
- 8774/3: Spindle cell melanoma, type B
- 8780/3: Blue nevus, malignant
- 8790/3: Cellular blue nevus

**Total Unique Morphology Codes:** 500+ histologic types

---

## üìä SEER SITE RECODE GROUPINGS

**Purpose:** Aggregate ICD-O-3 codes into ~70 analytic cancer site groups

### **SEER Site Recode ICD-O-3/WHO 2008:**

| Recode # | Site Group | ICD-O-3 Sites | Major Histologies |
|----------|------------|---------------|-------------------|
| **20010** | Lip | C00.0-C00.9 | Squamous cell carcinoma |
| **20020** | Tongue | C01, C02.0-C02.9 | Squamous cell carcinoma |
| **20030** | Salivary gland | C07-C08.9 | Mucoepidermoid, adenoid cystic |
| **20040** | Floor of mouth | C04.0-C04.9 | Squamous cell carcinoma |
| **20050** | Gum and other mouth | C03.0-C03.9, C05.0-C06.9 | Squamous cell carcinoma |
| **20060** | Nasopharynx | C11.0-C11.9 | Nasopharyngeal carcinoma |
| **20070** | Tonsil | C09.0-C09.9 | Squamous cell carcinoma |
| **20080** | Oropharynx | C10.0-C10.9 | Squamous cell carcinoma |
| **20090** | Hypopharynx | C12-C13.9 | Squamous cell carcinoma |
| **20100** | Other oral cavity and pharynx | C14.0-C14.8 | Squamous cell carcinoma |
| **21010** | Esophagus | C15.0-C15.9 | Adenocarcinoma, squamous |
| **21020** | Stomach | C16.0-C16.9 | Adenocarcinoma |
| **21030** | Small intestine | C17.0-C17.9 | Adenocarcinoma, carcinoid |
| **21041** | Cecum | C18.0 | Adenocarcinoma |
| **21042** | Appendix | C18.1 | Adenocarcinoma, carcinoid |
| **21043** | Ascending colon | C18.2 | Adenocarcinoma |
| **21044** | Hepatic flexure | C18.3 | Adenocarcinoma |
| **21045** | Transverse colon | C18.4 | Adenocarcinoma |
| **21046** | Splenic flexure | C18.5 | Adenocarcinoma |
| **21047** | Descending colon | C18.6 | Adenocarcinoma |
| **21048** | Sigmoid colon | C18.7 | Adenocarcinoma |
| **21049** | Large intestine, NOS | C18.8-C18.9, C26.0 | Adenocarcinoma |
| **21051** | Rectosigmoid junction | C19 | Adenocarcinoma |
| **21052** | Rectum | C20 | Adenocarcinoma |
| **21060** | Anus, anal canal, anorectum | C21.0-C21.8 | Squamous cell carcinoma |
| **21071** | Liver | C22.0 | Hepatocellular carcinoma |
| **21072** | Intrahepatic bile duct | C22.1 | Cholangiocarcinoma |
| **21080** | Gallbladder | C23 | Adenocarcinoma |
| **21090** | Other biliary | C24.0-C24.9 | Cholangiocarcinoma |
| **21100** | Pancreas | C25.0-C25.9 | Adenocarcinoma (ductal) |
| **21110** | Retroperitoneum | C48.0 | Sarcoma |
| **21120** | Peritoneum, omentum, mesentery | C48.1-C48.2 | Mesothelioma, sarcoma |
| **21130** | Other digestive organs | C26.8-C26.9 | Various |
| **22010** | Nose, nasal cavity, middle ear | C30.0-C30.1, C31.0-C31.9 | Squamous, adenocarcinoma |
| **22020** | Larynx | C32.0-C32.9 | Squamous cell carcinoma |
| **22030** | Lung and bronchus | C34.0-C34.9 | Adenocarcinoma, squamous, small cell |
| **22050** | Pleura | C38.4 | Mesothelioma |
| **22060** | Trachea, mediastinum, other | C33, C38.0-C38.3, C38.8, C39.0-C39.9 | Various |
| **23000** | Bones and joints | C40.0-C41.9 | Osteosarcoma, Ewing, chondrosarcoma |
| **24000** | Soft tissue (including heart) | C38.0, C47.0-C49.9 | Sarcomas (various subtypes) |
| **25010** | Melanoma of the skin | C44.0-C44.9 | Malignant melanoma (8720-8790) |
| **25020** | Other non-epithelial skin | C44.0-C44.9 | Sarcomas, lymphomas (excluding 8050-8084, 8090-8110) |
| **26000** | Breast | C50.0-C50.9 | Ductal, lobular carcinoma |
| **27010** | Cervix uteri | C53.0-C53.9 | Squamous, adenocarcinoma |
| **27020** | Corpus uteri | C54.0-C54.9 | Endometrial adenocarcinoma |
| **27030** | Uterus, NOS | C55 | Adenocarcinoma, sarcoma |
| **27040** | Ovary | C56 | Serous, mucinous, endometrioid, clear cell |
| **27050** | Vagina | C52 | Squamous cell carcinoma |
| **27060** | Vulva | C51.0-C51.9 | Squamous cell carcinoma |
| **27070** | Other female genital organs | C57.0-C57.9 | Serous carcinoma |
| **28010** | Prostate | C61 | Adenocarcinoma |
| **28020** | Testis | C62.0-C62.9 | Seminoma, nonseminomatous germ cell |
| **28030** | Penis | C60.0-C60.9 | Squamous cell carcinoma |
| **28040** | Other male genital organs | C63.0-C63.9 | Various |
| **29010** | Urinary bladder | C67.0-C67.9 | Urothelial carcinoma |
| **29020** | Kidney and renal pelvis | C64, C65 | Renal cell carcinoma, urothelial |
| **29030** | Ureter | C66 | Urothelial carcinoma |
| **29040** | Other urinary organs | C68.0-C68.9 | Urothelial carcinoma |
| **30000** | Eye and orbit | C69.0-C69.9 | Melanoma, retinoblastoma |
| **31010** | Brain | C71.0-C71.9 | Glioblastoma, astrocytoma |
| **31040** | Other nervous system | C70.0-C70.9, C72.0-C72.9 | Meningioma, ependymoma |
| **32010** | Thyroid | C73 | Papillary, follicular, medullary, anaplastic |
| **32020** | Other endocrine (thymus, adrenal, other) | C37, C74.0-C75.9 | Thymoma, adrenocortical, neuroendocrine |
| **33011** | Hodgkin lymphoma - Nodal | C00.0-C80.9 | Hodgkin (9650-9667) |
| **33012** | Hodgkin lymphoma - Extranodal | C00.0-C80.9 | Hodgkin (9650-9667) |
| **33041** | NHL - Nodal | C00.0-C80.9 | Non-Hodgkin (9590-9729, excl 9650-9667) |
| **33042** | NHL - Extranodal | C00.0-C80.9 | Non-Hodgkin (9590-9729, excl 9650-9667) |
| **34000** | Myeloma | C00.0-C80.9 | Plasma cell myeloma (9732, 9733) |
| **35011** | Acute lymphocytic leukemia | C00.0-C80.9 | ALL (9826, 9835, 9836, etc.) |
| **35012** | Chronic lymphocytic leukemia | C00.0-C80.9 | CLL (9823) |
| **35013** | Other lymphocytic leukemia | C00.0-C80.9 | Various lymphoid (9820-9949) |
| **35021** | Acute myeloid leukemia | C00.0-C80.9 | AML (9840, 9861, 9865-9874, 9895-9897, 9898, 9910-9911, 9920) |
| **35022** | Chronic myeloid leukemia | C00.0-C80.9 | CML (9863, 9875, 9876, 9945, 9946) |
| **35023** | Other myeloid/monocytic leukemia | C00.0-C80.9 | Various myeloid (9840-9931) |
| **35031** | Other acute leukemia | C00.0-C80.9 | Other acute (9801, 9805, 9931) |
| **35032** | Aleukemic, subleukemic, NOS | C00.0-C80.9 | Leukemia NOS (9800, 9804, 9820) |
| **35041** | Chronic myeloproliferative disorders | C00.0-C80.9 | MPD (9950-9964) |
| **35043** | Myelodysplastic syndromes | C00.0-C80.9 | MDS (9980-9989) |
| **36010** | Mesothelioma | C00.0-C80.9 | Mesothelioma (9050-9055) |
| **36020** | Kaposi sarcoma | C00.0-C80.9 | Kaposi (9140) |
| **37000** | Miscellaneous malignant cancer | C00.0-C80.9 | Other specified histologies |

**Total SEER Site Recode Groups:** ~70 categories

---

## üîç HOW TO USE SEER DATA FOR COUNTY-LEVEL RESEARCH

### **Step 1: Access SEER Data**

**Option A: SEER*Stat Public-Use Data (Limited Geographic Detail)**

```r
# SEER*Stat: https://seer.cancer.gov/seerstat/
# Download software: https://seer.cancer.gov/seerstat/download/

# Request public-use data:
# - SEER 22 Registries (48% US population)
# - State & county FIPS available for some registries
# - Data dictionary: https://seer.cancer.gov/data-software/documentation/seerstat/

# Example: SEER*Stat session export ‚Üí CSV
library(tidyverse)

seer_incidence <- read_csv("seer22_county_incidence_2000_2021.csv")

# Variables typically include:
# - Year of diagnosis
# - County FIPS (where available)
# - Age at diagnosis (grouped)
# - Race/ethnicity
# - Sex
# - Site recode
# - Histology recode
# - Stage at diagnosis (SEER Summary Stage)
# - Count (cases)
# - Population (denominator)
# - Age-adjusted rate (per 100,000)
```

**Option B: SEER Research Data (Requires DUA) - More Geographic Detail**

```r
# Request via: https://seer.cancer.gov/data/access.html
# Requires:
# 1. Research proposal
# 2. IRB approval
# 3. Data Use Agreement
# 4. Secure environment

# Provides patient-level data with:
# - Full ICD-O-3 site/histology
# - County or ZIP code
# - Exact age, date of diagnosis
# - Treatment details
# - Survival time

# Not available for immediate county-level analysis in this example
```

**Option C: State Cancer Registries via CDC Wonder**

```r
# CDC Wonder: https://wonder.cdc.gov/
# U.S. Cancer Statistics: https://www.cdc.gov/united-states-cancer-statistics/

# Download county-level data:
# 1. Select "United States Cancer Statistics - Incidence"
# 2. Group By: County, Site, Year
# 3. Measures: Count, Rate (age-adjusted)

uscs_county <- read_tsv("cdc_wonder_uscs_county_2001_2021.txt")

county_cancer <- uscs_county %>%
  select(
    state = State,
    county = County,
    fips = `County Code`,
    year = Year,
    site = `Cancer Sites`,
    cases = Count,
    pop = Population,
    rate_agestd = `Age Adjusted Rate`
  )
```

---

### **Step 2: Calculate County Incidence Rates by Cancer Type**

```r
library(tidycensus)

# Get county population for denominator
county_pop_2020 <- get_acs(
  geography = "county",
  variables = "B01003_001",
  year = 2020
) %>%
  mutate(fips = GEOID) %>%
  select(fips, population = estimate)

# Calculate incidence rates
county_cancer_rates <- county_cancer %>%
  filter(year == 2020) %>%
  left_join(county_pop_2020, by = "fips") %>%
  group_by(fips, site) %>%
  summarize(
    cases = sum(cases),
    population = first(population),
    crude_rate = (cases / population) * 100000
  )

# Top cancers by county
top_cancers_per_county <- county_cancer_rates %>%
  group_by(fips) %>%
  slice_max(cases, n = 5) %>%
  ungroup()
```

---

### **Step 3: Map Cancer Incidence by County**

```r
library(sf)
library(ggplot2)
library(tigris)

# Load county boundaries
counties_sf <- counties(year = 2020, cb = TRUE)

# Join lung cancer data
lung_cancer_map <- counties_sf %>%
  mutate(fips = GEOID) %>%
  left_join(
    county_cancer_rates %>% filter(site == "Lung and Bronchus"),
    by = "fips"
  )

# Map lung cancer incidence
ggplot(lung_cancer_map) +
  geom_sf(aes(fill = crude_rate), color = NA) +
  scale_fill_viridis_c(
    name = "Lung Cancer Incidence\n(per 100,000)",
    option = "plasma",
    na.value = "grey90"
  ) +
  theme_minimal() +
  labs(title = "Lung Cancer Incidence by US County, 2020")
```

---

### **Step 4: Link Cancer Incidence to Environmental Exposures**

```r
# Join with environmental data (e.g., PM2.5, radon, pesticides)
library(readr)

pm25_county <- read_csv("cdc_pm25_county_2020.csv")
radon_county <- read_csv("epa_radon_county.csv")
smoking_county <- read_csv("cdc_brfss_smoking_county_2020.csv")

cancer_environment <- county_cancer_rates %>%
  filter(site == "Lung and Bronchus") %>%
  left_join(pm25_county, by = "fips") %>%
  left_join(radon_county, by = "fips") %>%
  left_join(smoking_county, by = "fips")

# Regression: Lung cancer incidence ~ PM2.5 + radon + smoking
model <- lm(crude_rate ~ pm25_mean + radon_avg_pci + smoking_prev,
            data = cancer_environment)

summary(model)
```

---

## üìö COMPANION CANCER DATA SOURCES

### **National Program of Cancer Registries (NPCR):**
- CDC cancer surveillance
- Covers additional states beyond SEER
- Portal: https://www.cdc.gov/united-states-cancer-statistics/

### **North American Association of Central Cancer Registries (NAACCR):**
- Registry standards
- Combined SEER + NPCR data
- Portal: https://www.naaccr.org/

---

## üìà TEMPORAL & SPATIAL COVERAGE

| Attribute | Details |
|-----------|---------|
| **SEER Program Coverage** | 1973-present (original 9 registries), 1992-present (expanded to 18), 2000-present (22 registries) |
| **Population Coverage** | 48% of US population (SEER 22) |
| **Geographic Detail (Public)** | State and county FIPS (some registries) |
| **Geographic Detail (Restricted)** | Patient ZIP code, census tract (research data) |
| **Temporal Resolution** | Year and month of diagnosis |
| **Update Frequency** | Annual (released November each year, 2-year lag) |

---

## ‚ö†Ô∏è DATA QUALITY & LIMITATIONS

### **Strengths:**
- Gold standard for US cancer surveillance
- Complete ascertainment within registry areas (>95%)
- Detailed ICD-O-3 coding (site, histology, behavior, grade)
- Long-term follow-up for survival
- Quality-controlled by NAACCR

### **Limitations:**
- **Geographic coverage:** 48% of US (not nationally representative for all counties)
- **County-level data:** Public-use data often limited to state-level or select registries
- **Lag time:** 2 years between diagnosis and public data release
- **Small area instability:** County-level rates unreliable for rare cancers
- **No exposure data:** Registry has diagnosis/treatment, not environmental/behavioral risk factors
- **Privacy suppression:** Counts <16 often suppressed in public data

---

## üìù CITATION

**When using SEER data, cite:**

> Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Data, 22 Registries, Nov 2023 Sub (2000-2021) - Linked To County Attributes - Time Dependent (1990-2021) Income/Rurality, 1969-2022 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2024, based on the November 2023 submission.

**For ICD-O-3 codes:**

> International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization; 2020.

---

**Last Updated:** November 13, 2025
**ICD-O Version:** ICD-O-3.2 (current standard for 2021+), Cancer PathCHART 2024 (for 2024+ cases)
**Total Cancer Types:** 1,000+ unique site-histology combinations (400+ sites √ó 500+ histologies with behavior modifiers)
